Compared with patients with low levels of both IL-6 and IL-1β, patients with high levels of both IL-6 and IL-1β have significantly shorter overall survival and progression-free survival, a lower tumor control rate, and a reduced high-dose intensity of GEM (96). This evidence concerns the gene IL1B and neoplasm.